News & Videos - SMITH & NEPHEW ORD USD0.20

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal , 1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE have reviewed ‘ Medical Technology Guideline 43 PICO negative pressure wound dressings for closed surgical incisions’ which recognises that Smith+Nephew’s PICO sNPWT provides better clinical outcomes than standard...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn, 1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities. 1 It is estimated that the annual financial burden...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC’s immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN ◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. 1 Developed to restore patients’ range-of-motion 2-5...

Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* for its CORI ◊ Surgical System, this exclusive image-agnostic* robotic-assisted surgical solution is designed to further help personalize surgery, advance efficiencies, and optimize performance across Smith+Nephew’s orthopaedic reconstruction portfolio. The power of one robotic-assisted platform...

12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant alongside the REGENETEN ◊ Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and...

First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December , the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the...

Une étude contrôlée randomisé (ECR) multicentrique récemment publié démontre que la Thérapie par Pression Négative (TPN)à usage unique PICO ◊ , proposée par Smith+Nephew, est supérieur à une TPN traditionnelle pour réduire la surface, la profondeur et le volume des plaies d'ulcérations veineuses de la jambe (UVJ) et d'ulcères du pied diabétique (UPD) Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici :...

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared to traditional negative pressure wound therapy (tNPWT) in patients with lower extremity ulcers. 1* This press release features multimedia. View the full release here:...

UK’s NICE Publishes a Medtech Innovation Briefing on PICO™ for the Prophylactic Use in Surgically Closed Incisions to Reduce Surgical Site Complications PR Newswire LONDON and NEW YORK, July 3, 2018 LONDON and NEW YORK , July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of PICO Single Use Negative...